Latest Prostate Cancer Treatments in 2026: New Drugs, PSMA Therapy & Targeted Treatment

2026 evidence update: Newer treatments are not interchangeable. PARP-targeted treatments depend on molecular findings and previous therapy; lutetium-177 PSMA treatment requires appropriate disease status and PSMA-based eligibility assessment. Castration-resistant disease generally requires continued ADT alongside selected additional therapies. Approval and reimbursement differ by country. See EAU treatment recommendations.

There Is No Single “Newest” Treatment for Every Prostate Cancer

Prostate cancer is now treated increasingly as several biologically different diseases rather than one condition with one standard sequence.

A treatment that is appropriate for a man with:

• low-risk localized cancer;
• PSA recurrence after surgery;
• newly metastatic hormone-sensitive disease; or
• heavily pretreated metastatic castration-resistant disease

may be completely inappropriate for another patient.

The most important modern change is therefore matching treatment to disease state and tumor biology.

What Changed Most in 2026?

1. Pluvicto Moved Earlier in Metastatic Disease

On July 31, 2026, the FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in combination with an androgen-receptor pathway inhibitor (ARPI) for adults with PSMA-positive metastatic androgen-pathway-modulation-naïve or -sensitive prostate cancer.

This disease state has traditionally been called metastatic hormone-sensitive prostate cancer (mHSPC/mCSPC).

Patients must be selected using an approved PSMA PET imaging test demonstrating appropriate PSMA expression.

This is important because PSMA radioligand therapy had previously been used primarily later in the treatment pathway.

2. PTEN-Deficient Disease Gained a Targeted Option

On June 12, 2026, the FDA approved capivasertib (Truqap) with abiraterone and prednisone for adults with newly diagnosed metastatic androgen-pathway-modulation-naïve/sensitive prostate cancer whose tumors are PTEN-deficient by an FDA-authorized test.

Capivasertib inhibits AKT signaling, targeting a pathway that becomes important when PTEN tumor-suppressor function is lost.

This makes PTEN testing clinically actionable in an earlier metastatic setting.

3. BRCA2-Targeted PARP Treatment Moved Earlier

On December 12, 2025, FDA approved the fixed combination niraparib + abiraterone (Akeega) with prednisone for adults with BRCA2-mutated metastatic castration-sensitive prostate cancer.

All patients continue androgen deprivation therapy or have undergone orchiectomy.

This is another example of targeted treatment moving earlier rather than being reserved only for late castration-resistant disease.

Modern Treatment by Disease State

1. Earlier Treatment Intensification With ADT + ARPI

One of the most important modern advances happened before the newest 2026 approvals.

For most fit men presenting with metastatic hormone-sensitive prostate cancer, current EAU guidance recommends not using ADT alone when combination therapy is suitable.

ADT is generally combined with a modern androgen-receptor pathway inhibitor such as:

• abiraterone + prednisone/prednisolone;
• apalutamide;
• enzalutamide; or
• darolutamide in appropriate settings.

For selected chemotherapy-fit men, treatment can be intensified further with:

ADT + docetaxel + an appropriate ARPI.

See our hormone therapy for prostate cancer guide.

2. PSMA Radioligand Therapy

PSMA-targeted radioligand therapy is one of the most important advances in advanced prostate cancer.

PSMA stands for prostate-specific membrane antigen, a protein highly expressed by many prostate-cancer cells.

A PSMA PET scan identifies whether sufficient tumor deposits express the target.

Pluvicto carries radioactive lutetium-177 directly to PSMA-expressing cancer cells, allowing localized radiation damage throughout the body.

How the Pluvicto Indication Has Expanded

• Earlier established role: PSMA-positive mCRPC after ARPI and taxane treatment.
• March 28, 2025: FDA expanded use to PSMA-positive mCRPC after ARPI when delaying taxane chemotherapy is appropriate.
• July 31, 2026: FDA moved Pluvicto substantially earlier by approving it with an ARPI in selected PSMA-positive metastatic androgen-pathway-modulation-naïve/sensitive disease.

This progression illustrates how a treatment initially used late in advanced disease can move earlier when randomized trials demonstrate benefit.

3. Capivasertib for PTEN-Deficient Metastatic Disease

PTEN is a tumor-suppressor protein involved in controlling the PI3K/AKT signaling pathway.

Loss of PTEN can drive aggressive prostate-cancer biology.

Capivasertib inhibits AKT and is now FDA-approved with:

• abiraterone;
• prednisone; and
• ongoing ADT

for selected metastatic androgen-pathway-modulation-naïve/sensitive cancers that are PTEN-deficient.

This is not a treatment for all prostate cancer. A validated companion diagnostic is required.

4. PARP Inhibitors and BRCA/HRR Testing

PARP inhibitors exploit defects in DNA-repair pathways.

They are particularly important in tumors with alterations such as BRCA1/2 and other homologous recombination repair (HRR) genes.

Modern prostate-cancer therapy includes several PARP-based approaches, depending on exact mutation, disease state and regulatory indication:

• olaparib;
• rucaparib;
• olaparib + abiraterone;
• niraparib + abiraterone; and
• talazoparib + enzalutamide.

Current EAU guidance emphasizes genomic testing in metastatic prostate cancer because BRCA/HRR results can directly change treatment selection.

5. PSMA PET Has Changed Treatment Planning

PSMA PET is not itself a cancer treatment, but it has changed how treatment is selected.

It can detect prostate-cancer deposits that conventional CT and bone scans may miss.

EAU cites randomized evidence showing markedly better staging accuracy in high-risk prostate cancer compared with conventional imaging.

PSMA PET now helps guide:

• primary staging;
• recurrence evaluation;
• salvage radiation planning;
• metastasis-directed treatment; and
• eligibility for PSMA radioligand therapy.

See our prostate cancer recurrence guide.

6. Modern Radiation Has Become Shorter and More Precise

“New treatment” does not only mean new drugs.

Modern radiation now includes:

• IMRT/VMAT with daily image guidance;
• moderate hypofractionation;
• SBRT/ultra-hypofractionation in selected men;
• LDR and HDR brachytherapy;
• MRI-guided or MRI-informed planning;
• selected focal dose escalation to dominant intraprostatic lesions; and
• proton therapy in specialist centers.

Many modern courses are significantly shorter than historical 8–9 week radiation schedules.

For the complete evidence, see prostate cancer radiation therapy.

7. Is Proton Therapy a New Superior Treatment?

Proton therapy is technologically sophisticated, but newer does not mean clinically superior.

The randomized PARTIQoL trial found similarly high quality of life and tumor control with proton therapy and modern IMRT for low- and intermediate-risk localized prostate cancer.

Protons can reduce the radiation dose delivered beyond the target, but no universal superiority in cancer control or meaningful side effects has been demonstrated.

See proton therapy vs IMRT.

8. Brachytherapy Still Has an Important Modern Role

Permanent radioactive seed implantation is not a historical treatment that has been replaced by newer technologies.

Modern LDR and HDR brachytherapy remain effective options in carefully selected localized disease and can be used as a dose-escalating boost in some higher-risk cancers.

Patient selection depends heavily on:

• risk group;
• baseline urinary function;
• prostate size/anatomy; and
• whether external-beam radiation and ADT are also needed.

See our prostate brachytherapy guide.

9. Better Salvage Treatment After Recurrence

Modern recurrence treatment has become much more precise.

After radical prostatectomy, early salvage radiation can still be curative and is most effective when PSA remains low.

PSMA PET can identify nodal or distant disease and help guide:

• prostate-bed radiation;
• pelvic-node radiation;
• metastasis-directed SBRT; and
• systemic-treatment decisions.

After radiotherapy, selected men with biopsy-proven localized recurrence can sometimes receive:

• salvage prostatectomy;
• salvage LDR/HDR brachytherapy;
• salvage SBRT;
• cryotherapy; or
• HIFU in specialist/trial settings.

Read prostate cancer recurrence, PSA rise and salvage treatment.

10. Sipuleucel-T: An Established Cancer “Vaccine”

Sipuleucel-T (Provenge) is not a new 2026 treatment, but it remains a distinctive immunotherapy for selected men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.

It is a personalized autologous cellular immunotherapy rather than a preventive vaccine.

See Provenge and prostate cancer vaccines.

11. Pembrolizumab for a Small Molecular Subgroup

Immune checkpoint inhibitors have not produced major benefits in unselected prostate cancer.

However, pembrolizumab can be clinically important in tumors with rare biomarkers such as:

• microsatellite instability-high (MSI-H); or
• deficient mismatch repair (dMMR).

This is another reason molecular testing matters in advanced disease.

12. Chemotherapy Is Still Important

Newer drugs have not made chemotherapy obsolete.

Docetaxel remains important in:

• selected metastatic hormone-sensitive treatment intensification; and
• metastatic castration-resistant disease.

Cabazitaxel is especially important after docetaxel and prior AR-pathway therapy.

Current EAU guidance specifically discourages simply switching repeatedly from one ARPI to another when cross-resistance is likely and recommends choosing treatment according to prior response, disease burden, symptoms and genomic profile.

13. Radium-223 for Selected Bone-Predominant Disease

Radium-223 is a radiopharmaceutical that targets areas of active bone turnover.

It has a role in selected metastatic castration-resistant prostate cancer with bone metastases.

It is not interchangeable with Pluvicto:

• radium-223 targets bone biology;
• Pluvicto targets PSMA-expressing cancer cells.

Bone-protective therapy and fracture risk must also be considered carefully with advanced prostate-cancer treatment.

14. Denosumab: Important, But Not a New Anticancer Cure

The old version of this article described denosumab among new monoclonal-antibody cancer treatments.

Denosumab is a monoclonal antibody against RANKL.

In prostate cancer, its major role is to reduce skeletal complications or protect bone in appropriate clinical settings—not to directly eliminate the prostate-cancer tumor.

It can be used to:

• reduce skeletal-related events in selected metastatic bone disease; or
• manage treatment-related osteoporosis/fracture risk in selected patients.

Important risks include hypocalcemia and osteonecrosis of the jaw, so calcium/vitamin D status and dental health require attention.

What Happened to Anti-Angiogenic Drugs?

The old page presented anti-angiogenic drugs—therapies designed to block tumor blood-vessel growth—as an important emerging prostate-cancer strategy.

That approach did not become a standard treatment pathway for prostate cancer.

Agents targeting VEGF/angiogenesis were studied extensively, but they failed to establish the kind of survival benefit and clinical role ultimately achieved by:

• ARPIs;
• taxane chemotherapy;
• PARP inhibitors;
• PSMA radioligand therapy; and
• other biomarker-directed treatments.

Anti-angiogenesis should therefore be presented as historical/experimental research, not as a leading current prostate-cancer treatment.

What About Nerve Grafts After Prostate Surgery?

The legacy article described nerve grafting as a major new strategy for restoring erectile function after prostatectomy.

Nerve grafting has been studied, but it is not established routine standard-of-care treatment for post-prostatectomy erectile dysfunction.

Modern prostatectomy focuses instead on:

• appropriate nerve-sparing when oncologically safe;
• high-quality surgical technique;
• baseline erectile-function counseling; and
• post-treatment ED management with PDE5 inhibitors, vacuum devices, injections or penile prosthesis when necessary.

Are Focal Treatments “New Cures”?

Techniques such as:

• HIFU;
• cryotherapy;
• focal laser treatment; and
• other focal ablation approaches

are attractive because they aim to treat only the cancer-containing region while preserving more prostate tissue.

However, prostate cancer can be multifocal, and long-term comparative evidence is less mature than for surgery or radiation.

Focal treatment should therefore be offered only in carefully selected settings with appropriate counseling, preferably within experienced protocols or prospective registries/trials where guidelines recommend this.

Can New Treatments Cure Stage 4 Prostate Cancer?

Most metastatic stage IV prostate cancers are still treated with the goal of long-term disease control rather than guaranteed cure.

But survival has improved substantially because effective therapies are now:

• combined earlier;
• selected by biomarkers;
• sequenced more intelligently; and
• supported by better imaging.

A diagnosis of metastatic disease should therefore not be interpreted using survival expectations from treatment eras before modern ARPIs, PARP inhibitors and PSMA-directed therapy.

See our advanced prostate cancer guide.

Which Tests Now Matter Before Choosing Advanced Treatment?

Modern treatment decisions may require more than PSA and a standard CT scan.

Depending on disease state, useful tests can include:

• PSMA PET/CT;
• germline genetic testing;
• somatic tumor genomic testing;
• BRCA1/2 and other HRR genes;
• PTEN testing;
• MSI/MMR testing;
• testosterone level during ADT; and
• repeat tissue or liquid-biopsy testing when clinically justified.

These tests are increasingly used to identify who is most likely to benefit from a particular therapy.

How Should “Latest Treatment” Be Evaluated?

When reading about a new prostate-cancer treatment, ask:

1. Has it been tested in a randomized phase III trial?
2. Did it improve overall survival, progression-free survival or another meaningful endpoint?
3. Which exact disease state was studied?
4. Was treatment limited to patients with a biomarker?
5. Is it FDA/EMA approved for that exact use?
6. What treatment had patients already received?
7. What are the major toxicities?
8. Is the benefit large enough to matter for this individual patient?

Questions to Ask Your Oncology Team About New Treatments

1. What exact disease state do I have now?
2. Is my cancer still hormone-sensitive or castration-resistant?
3. Have I had germline and somatic genomic testing?
4. Do I have a BRCA/HRR alteration?
5. Is my tumor PTEN-deficient?
6. Do I need MSI/MMR testing?
7. Am I PSMA-positive on an appropriate PET scan?
8. Would Pluvicto be appropriate now or later?
9. Should my ADT be intensified with an ARPI or chemotherapy?
10. Is a PARP-based treatment relevant to my tumor?
11. Would a clinical trial offer something genuinely unavailable with standard treatment?
12. What benefit should I realistically expect, and what are the major risks?

Medical information notice: Prostate-cancer treatment changes rapidly and regulatory approvals differ by country. Drug choice requires oncology assessment of disease state, previous treatment, biomarker results, comorbidities and the exact approved indication.